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Macrophage migration Inhibitory Factor (MIF) is a pro-inﬂammatory molecule able
to sustain exaggerated Gram negative inﬂammatory responses by inducing Toll-like
receptor-4 expression. A MIF regulatory role in CF was suggested by evidences
that the 5-CATT polymorphism repeat (MIF5), with lowest promoter activity, was
associated with a milder disease phenotype in CF patients with different CFTR
genotypes (Barry J et al., Am J Respir Crit Care Med, 2005). Allele frequencies
were determined in 134 non-CF and 189 CF patients homozygous for F508del-
CFTR mutation with the goal to assess association between CATT polymorphism
and disease severity. DNA was ampliﬁed using the forward and reverse primers
as described (Baugh JA et al., Genes & Immunity, 2002) and PCR results were
analyzed using GenescanView 1.2 software. In this multicenter study, key clinical
features of F508del homozygous CF patients were recorded. Patients with MIF5
displayed concordant trends to better nutritional status, lower diabetes incidence
and slower decrease of FEV1 in comparison with those carrying other polymorphic
alleles. Quartile analysis based on Kulich’s normalized FEV1 showed that MIF5
is associated to a better lung function expressed as FEV1 (p = 0.03). Kaplan–
Meier analysis showed a delay in ﬁrst measurement of FEV1 <60% (p = 0.03)
in MIF5 patients. This work provides compelling support for a regulatory role of
MIF in the severity of CF disease highlighting the relevant roles of macrophages
in CF.
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